Zhang Tong, He Wen-Ting, Zi Ming-Jie, Song Gang, Yi Dan-Hui, Yang Yu-Fei
Department of Oncology, Xiyuan Hospital of China Academy of Chinese Medicial Sciences, Beijing, 100091, China.
Second Department of Oncology, Traditional Chinese Medicine, Hospital Affiliated to Xinjiang Medical University, Urumchi, 830001, China.
Chin J Integr Med. 2018 Aug;24(8):573-578. doi: 10.1007/s11655-018-2980-0. Epub 2018 May 22.
To investigate the efficacy of integrated Chinese and Western medicine (IM) in the treatment of metastatic colorectal cancer (mCRC) in a cohort study.
The survival outcome of patients receiving IM was compared with that of patients receiving Western medicine alone. The study design was adopted with "continuous administration of Chinese medicine for ⩾ 3 months" as the exposure factor. Patients who met this exposure factor were assigned to the IM cohort (Group A, 110 patients). Patients who did not meet this exposure factor were assigned to the Western medicine cohort (Group B, 225 patients). The overall survival (OS), progression-free survival (PFS), and 1st year, 2nd year, and 3rd year survival in the two cohorts were compared.
The median OS in Group A and B were 18 months [95% confidence interval (CI) 15-21] and 16 months (95% CI 14-18), respectively, and the median PFS in Group A and B were 6 months (95% CI 4-7) and 5 months (95% CI 4-6), respectively. No statistically significant differences were observed between the groups (P=0.186, P=0.223). Group A demonstrated significantly longer OS and PFS than Group B in the following subgroups: female patients, patients with lesions in the right half of the colon, and those who received first-line treatment (P<0.05). In the subgroup of elderly patients (age>65 years), the OS in Group A was longer than that in Group B (P<0.05).
IM could prolong the survival of patients with mCRC. (Registry No. ChiCTR-IOR-17010497).
在一项队列研究中探讨中西医结合疗法（IM）治疗转移性结直肠癌（mCRC）的疗效。
将接受中西医结合疗法的患者与仅接受西医治疗的患者的生存结局进行比较。研究设计采用“连续服用中药≥3个月”作为暴露因素。符合该暴露因素的患者被分配到中西医结合疗法队列（A组，110例患者）。不符合该暴露因素的患者被分配到西医队列（B组，225例患者）。比较两组的总生存期（OS）、无进展生存期（PFS）以及第1年、第2年和第3年的生存率。
A组和B组的中位OS分别为18个月[95%置信区间（CI）15 - 21]和16个月（95%CI 14 - 18），A组和B组的中位PFS分别为6个月（95%CI 4 - 7）和5个月（95%CI 4 - 6）。两组之间未观察到统计学显著差异（P = 0.186，P = 0.223）。在以下亚组中，A组的OS和PFS显著长于B组：女性患者、结肠右半侧有病变的患者以及接受一线治疗的患者（P < 0.05）。在老年患者（年龄>65岁）亚组中，A组的OS长于B组（P < 0.05）。
中西医结合疗法可延长mCRC患者的生存期。（注册号：ChiCTR - IOR - 17010497）
